Vaccine: MenHibrix
Company: GlaxoSmithKline
Approval Date: June 14
Protects Against: Meningitis

GlaxoSmithKline's ($GSK) MenHibrix is the only non-influenza vaccine the FDA approved in 2012. MenHibrix combines vaccines to prevent disease from meningococcal groups C and Y as well as Haemophilus influenzae type b, or Hib. U.S. regulators have licensed the vaccine to be given to infants and children as young as 6 weeks to 18 months of age, according to the FDA. Vaccines for Hib began flooding the market back in the 1980s. But MenHibrix has an edge because healthcare providers can give it to patients as young as 6 weeks old.

GSK received another feather in its cap when a U.S. Centers for Disease Control panel recommended MenHibrix for bacterial meningitis for use in babies at increased risk of infection. The vaccine can also be used in babies aged 2 months through 18 months who live in communities battling outbreaks of meningococcal disease caused by serogroups C and Y.

For more:
CDC green-lights GSK's meningitis vaccine for at-risk infants
GSK grabs FDA nod for combo meningitis vax
FDA green-lights GSK's MenHibrix


Suggested Articles

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan

On the heels of last week's deal for 120 million Pfizer-BioNTech shots, Japan has locked down 120 million more vaccines from AstraZeneca.

The pandemic price could be lowered for larger deals, CEO Stephane Bancel said. Pfizer and BioNTech priced 100M doses at $19.50 each for the U.S.